These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7783285)

  • 41. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
    Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
    Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children--United States, 2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Jul; 51(26):574. PubMed ID: 12139185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
    Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
    Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine.
    Rendi-Wagner P; Kundi M; Mikolasek A; Vécsei A; Frühwirth M; Kollaritsch H
    Vaccine; 2006 Aug; 24(33-34):5960-5. PubMed ID: 16757063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology.
    Sheridan SL; Frith K; Snelling TL; Grimwood K; McIntyre PB; Lambert SB
    Expert Rev Vaccines; 2014 Sep; 13(9):1081-106. PubMed ID: 25093268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined acellular pertussis vaccines: new indication. No tangible benefit in primary vaccination.
    Prescrire Int; 2002 Jun; 11(59):73-5. PubMed ID: 12068840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
    Blennow M; Granström M
    Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Laboratory assessment problems of the efficacy of acellular pertussis vaccines].
    Gzyl A
    Przegl Epidemiol; 2004; 58(2):361-7. PubMed ID: 15517817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
    Meyer CU; Zepp F; Decker M; Lee M; Chang SJ; Ward J; Yoder S; Bogaert H; Edwards KM
    Clin Vaccine Immunol; 2007 Mar; 14(3):288-92. PubMed ID: 17267589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of acellular pertussis vaccines.
    Sato Y; Sato H
    Biologicals; 1999 Jun; 27(2):61-9. PubMed ID: 10600185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whooping cough, twenty years from acellular vaccines introduction.
    Greco D; Esposito S; Tozzi A; Pandolfi E; Icardi G; Giammanco A
    Ann Ig; 2015; 27(2):415-31. PubMed ID: 26051141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).
    Ward JI; Cherry JD; Chang SJ; Partridge S; Keitel W; Edwards K; Lee M; Treanor J; Greenberg DP; Barenkamp S; Bernstein DI; Edelman R;
    Clin Infect Dis; 2006 Jul; 43(2):151-7. PubMed ID: 16779740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toward safer and more efficient pertussis vaccines.
    Wegmann A; Glück R
    Eur J Pediatr; 1996 Feb; 155(2):71-3. PubMed ID: 8775215
    [No Abstract]   [Full Text] [Related]  

  • 57. Acellular pertussis vaccine scores high in trial.
    Marwick C
    JAMA; 1995 Jun; 273(24):1892-3. PubMed ID: 7783285
    [No Abstract]   [Full Text] [Related]  

  • 58. Acellular pertussis vaccine hailed for infants.
    Marwick C
    JAMA; 1995 Aug; 274(6):446-7. PubMed ID: 7629938
    [No Abstract]   [Full Text] [Related]  

  • 59. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.
    Blennow M; Granström M; Jäätmaa E; Olin P
    Pediatrics; 1988 Sep; 82(3):293-9. PubMed ID: 3043367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acellular pertussis vaccines: what lies ahead?
    Wiedermann BL
    Contemp Pediatr; 1995 Sep; 12(9):25-8, 30, 32 passim. PubMed ID: 10155576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.